Barclays’s Day One Biopharmaceuticals DAWN Stock Holding History

Barclays’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-35,000	Closed	-$326K	–	5126
2025 Q4	$326K	Buy	+35,000	New	+$292K	﹤0.01%	4088
2025 Q2	–	Sell	-9,000	Closed	-$71.4K	–	5321
2025 Q1	$71.4K	Hold	9,000	–	–	﹤0.01%	4513
2024 Q4	$114K	Sell	9,000 -21,000	-70%	-$292K	﹤0.01%	4565
2024 Q3	$418K	Buy	+30,000	New	+$428K	﹤0.01%	3888

Other funds holding DAWN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's DAWN Position: Q2 2026 in Review

Barclays sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 30,163 shares — an estimated $647K sold.

Barclays first reported a position in DAWN in Q1 2022 and held it in 17 quarters. The position peaked at $2.72M in Q4 2025. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

Barclays reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
Barclays sold 30,163 Day One Biopharmaceuticals shares in Q2 2026, an estimated $647K.
Barclays first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 17 quarters.
Barclays's Day One Biopharmaceuticals position peaked at $2.72M in Q4 2025.
1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.